Recombinant Human Keratin, Type I Cytoskeletal 13 (KRT13) Protein (His&Myc)

Name: Recombinant Human Keratin, Type I Cytoskeletal 13 (KRT13) Protein (His&Myc)
Brand: Beta LifeScience
SKU: BLC-07398P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Product Overview

Description	Recombinant Human Keratin, Type I Cytoskeletal 13 (KRT13) Protein (His&Myc) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	P13646
Target Symbol	KRT13
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-10His&C-Myc
Target Protein Sequence	MSLRLQSSSASYGGGFGGGSCQLGGGRGVSTCSTRFVSGGSAGGYGGGVSCGFGGGAGSGFGGGYGGGLGGGYGGGLGGGFGGGFAGGFVDFGACDGGLLTGNEKITMQNLNDRLASYLEKVRALEEANADLEVKIRDWHLKQSPASPERDYSPYYKTIEELRDKILTATIENNRVILEIDNARLAADDFRLKYENELALRQSVEADINGLRRVLDELTLSKTDLEMQIESLNEELAYMKKNHEEEMKEFSNQVVGQVNVEMDATPGIDLTRVLAEMREQYEAMAERNRRDAEEWFHTKSAELNKEVSTNTAMIQTSKTEITELRRTLQGLEIELQSQLSMKAGLENTVAETECRYALQLQQIQGLISSIEAQLSELRSEMECQNQEYKMLLDIKTRLEQEIATYRSLLEGQDAKMIGFPSSAGSVSPRSTSVTTTSSASVTTTSNASGRRTSDVRRP
Expression Range	1-458aa
Protein Length	Full Length
Mol. Weight	57.0 kDa
Research Area	Signal Transduction
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Protein Families	Intermediate filament family
Database References	HGNC: 6415 OMIM: 148065 KEGG: hsa:3860 STRING: 9606.ENSP00000246635 UniGene: Hs.654550
Associated Diseases	White sponge nevus 2 (WSN2)
Tissue Specificity	Expressed in some epidermal sweat gland ducts (at protein level) and in exocervix, esophagus and placenta.

Gene Functions References

Oral white sponge nevus may manifest variable clinical features. The novel mutation found in the KRT13 gene is believed to add evidence for a mutational hotspot in the mucosal keratins PMID: 29476668
this study reports that KRT13 plays a directive role in prostate cancer bone, brain, and soft tissue metastases PMID: 27835867
Keratin 13 gene is epigenetically suppressed during TGFB1-induced epithelial-mesenchymal transition in a human keratinocyte cell line. PMID: 29326042
Four rare missense variants were identified (ACTBL2 rs73757391 (5q11.2), BTD rs200337373 (3p25.1), KRT13 rs150321809 (17q21.2) and MC2R rs104894658 (18p11.21)), but only MC2R rs104894668 had a large effect size (OR = 9.66). PMID: 27378695
KRT13 expression is associated with poor prognosis at multiple stages of disease progression PMID: 27711225
Loss of CK13 expression is associated with invasive oral squamous cell carcinoma. PMID: 26225699
Low KRT13 mRNA expression is associated with oral squamous cell carcinoma. PMID: 25735388
Decreased KRT13 was associated with Esophageal Squamous Cell Carcinoma. PMID: 25851906
Our data provide mechanistic insights into the epigenetic silencing of KRT13 genes in OSCC cells and might be useful for the development of diagnostic markers and novel therapeutic approaches against OSCCs. PMID: 25527207
keratin14 expression can be used to detect early epithelial dysplasia, and that keratin13 and keratin17 expression are useful for detecting neoplastic changes PMID: 24471966
Immunoexpression of CK13 and CK17 in light green-stained superficial cells was associated with more severe morphological atypia in tongue squamous cell carcinoma PMID: 24247036
Fluorescent keratin 13 integrates into the endogenous keratin cytoskeleton in human vulva carcinoma-derived A431 cells, thereby serving as a reliable marker of keratin dynamics. PMID: 23757496
Loss of K13 in oral carcinoma in situ is partly due to its gene repression, but may also be due to some unknown post-translational events. PMID: 22301701
Keratin 13 is a more specific marker of conjunctival epithelium than keratin 19. PMID: 21738394
CK13 expression is elevated in KB cells treated with all-trans retinoic acid or arsenic trioxide. PMID: 19489262
exhibits a regular expression pattern in luminal epithelial cells of secretory phase human endometrium PMID: 11906920
Metaplastic squamous cells differentiate with a decrease of CK18 and an increase of CK13 expression. PMID: 16836912
CK13 positive staining occurs in cervical squamous tumors and in mucinous cervical type adenocarcinomas, while there was no positive staining in non-neoplastic cervical glandular elements PMID: 16949723
The different ligand regulations of KRT13 are due to ligand-differential recruitment of ER and coactivators. PMID: 18951949

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.